

## Technology Appraisal Committee Meeting (Committee C) Manchester

**Minutes:** Confirmed

**Date and Time:** Tuesday 23 October 2018

<b>Present:</b>	1. Prof Stephen O'Brien (Chair) 2. Dr Alex Cale 3. Prof Andrea Manca 4. Mr David Chandler 5. Ms Gail Coster 6. Mr John Hampson 7. Dr Judith Wardle 8. Prof Matt Stevenson 9. Mr Michael Chambers 10. Dr Nigel Langford 11. Dr Paul Tappenden 12. Dr Peter Selby (Vice Chair) 13. Dr Prithwiraj Das 14. Dr Richard Nicholas 15. Dr Robert Forsyth	Present for all notes Present for notes 1 to 13 Present for all notes Present for all notes Present for notes 8 to 13 Present for all notes Present for all notes Present for all notes Present for all notes
-----------------	--	---

### **In attendance:**

Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Sheela Upadhyaya	Associate Director, National Institute for Health and Care Excellence	Present for notes 1 to 7
Jo Ekeledo	Project Manager, National Institute for Health and Care Excellence	Present for notes 1 to 7
Ellise Warren	Administrator, National Institute for Health and Care Excellence	Present for notes 1 to 7
Lulieth Torres	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 7
Thomas Strong	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 7

Frances Sutcliffe	Associate Director, National Institute for Health and Care Excellence	Present for notes 8 to 19
Stephanie Callaghan	Project Manager, National Institute for Health and Care Excellence	Present for notes 8 to 19
Pratit Shah	Administrator, National Institute for Health and Care Excellence	Present for notes 8 to 19
Abitha Senthinathan	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 8 to 13
Alexander Filby	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 8 to 19
Kirsty Pitt	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 14 to 19
Paul Tappenden	ERG Representative	Present for notes 1 to 4 & 14 to 16
Jean Hamilton	ERG Representative	Present for notes 1 to 4
Ana Duarte	ERG Representative	Present for notes 8 to 10
Mark Corbett	ERG Representative	Present for notes 8 to 10
Stephen Palmer	ERG Representative	Present for notes 8 to 10
Matt Stevenson	ERG Representative	Present for notes 14 to 16
Peter Clarke	CDF Clinical Lead	Present for notes 8 to 13
Adnan Manzur	Clinical expert	Present for notes 1 to 3.5
Wojtek Rakowicz	Clinical expert	Present for notes 1 to 3.5
Fiona Marley	NHS commissioning	Present for notes 1 to 3.5
Elizabeth Lockley	Patient expert	Present for notes 1 to 3.5
Gennadiy Ilyashenko	Patient expert	Present for notes 1 to 3.5

Liz Ryburn	Patient expert	Present for notes 1 to 3.5
Michael Tempest	Company representative	Present for notes 1 to 3.5
Ben Tichler	Company representative	Present for notes 1 to 3.5
David Kuzan	Company representative	Present for notes 8 to 9.4
João Vieira	Company representative	Present for notes 8 to 9.4
Alex Upton	Company representative	Present for notes 11 to 15.2
Inderjit Mandair	Company representative	Present for notes 11 to 15.2
Mandy Tonkinson	NICE observer	Present for notes 1 to 7
Sally Doss	NICE observer	Present for notes 1 to 7
Carl Boswell	NICE observer	Present for notes 1 to 7
Phil Ranson	NICE observer	Present for notes 1 to 7
Leslie Hayes	NICE observer	Present for all notes
David Tyldesley	NICE observer	Present for all notes
Alan Moore	NICE observer	Present for all notes
Emma Kent	NICE observer	Present for all notes
Tom Strong	NICE observer	Present for notes 8 to 13
Gail Woodland	External observer	Present for notes 8 to 9.4

## Notes

### Any other Business

1. None

### Appraisal of Nusinersen for treating spinal muscular atrophy [ID1069]

#### Part 1 – Open session

2. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) and representatives from Biogen International GmbH.
3. The Chair asked all committee members, experts, ERG and NICE staff present to declare any relevant interests
  - 3.1. Matt Stevenson declared a non-personal specific financial interest via his employer ScHARR he is funded by the Institute for Clinical and Economic Review (ICER) in the USA to help appraise nusinersen and another SMA technology.
    - 3.1.1. It was agreed that this declaration would not prevent Matt Stevenson from participating in this section of the meeting.
  - 3.2. Rob Forsyth declared a non-personal non-financial interest as he has limited direct involvement in the care of children with SMA (the clinical indication for nusinersen). He declared he has made a new diagnoses of SMA; and has close clinical colleagues who manage children with SMA. His colleagues are actively involved in nusinersen and other SMA treatment trials. He organised a conference in September 2018 on behalf of the European Paediatric Neurology Society at which access to expensive new treatments in child neurology.
    - 3.2.1. It was agreed that this declaration would not prevent Rob Forsyth from participating in this section of the meeting.
  - 3.3. Richard Nicholas declared a personal non direct financial interest as he has received funds for advisory boards and lectures from Biogen regarding products related to multiple sclerosis.
    - 3.3.1. It was agreed that this declaration would prevent Richard Nicholas from participating in this section of the meeting.

3.4. Paul Tappenden was participating as the ERG Representative for this appraisal.

3.5. No further conflicts of interest were declared for this appraisal.

**Part 2a – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting)**

4. The committee discussed confidential information submitted as part of this appraisal.

**Part 2b – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)**

5. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
6. The committee decision was based on consensus.
7. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

**Appraisal of Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies [ID1166]**

**Part 1 – Open session**

8. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Novartis Pharmaceuticals Ltd.
9. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
  - 9.1. Andrea Manca declared a personal specific non-financial interest as he was a co-investigator in NIHR and EU grants on Haematological malignancies. He also works for York ERG which is the same ERG used to review this appraisal.
    - 9.1.1. It was agreed that this declaration would not prevent Andrea Manca from participating in this section of the meeting.
  - 9.2. Stephen O'Brien declared a non-personal specific non-financial interest as his Trust is bidding to provide CAR-t cell therapy.

9.2.1. It was agreed that this declaration would not prevent Stephen O'Brien from participating in this section of the meeting.

9.3. Peter Selby declared a non-personal specific non-financial interest as his Trust is bidding to provide CAR-t cell therapy.

9.3.1. It was agreed that this declaration would not prevent Peter Selby from participating in this section of the meeting.

9.4. No further conflicts of interest were declared for this appraisal.

**Part 2a – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting)**

10. The committee discussed confidential information submitted as part of this appraisal.

**Part 2b – Closed session (company representatives, clinical and patient experts, ERG/ representatives and members of the public were asked to leave the meeting)**

11. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.

12. The committee decision was based on consensus.

13. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Appraisal of Regorafenib for previously treated advanced hepatocellular carcinoma [ID1519]**

**Part 1 – Open session**

14. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Bayer plc.

15. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

15.1. Matt Stevenson was the ERG representative for this topic and he was absent as the committee member for this appraisal.

15.2. No further conflicts of interest were declared for this appraisal.

**Part 2a – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting)**

16. The committee discussed confidential information submitted as part of this appraisal.

**Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)**

17. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.

18. The committee decision was based on consensus.

19. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

Tuesday 27 November 2018 from 10am to 5pm at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.